PTX Prescient Therapeutics Limited
Healthcare · Biotechnology
· website
$0.09
52wk 0.04 – 0.12
Overall
—
Value
—
Growth
—
Health
—
Quality
—
Momentum
—
Dividend
—
Price
About Prescient Therapeutics Limited
Prescient Therapeutics Limited, a clinical stage oncology company, develops drugs for the treatment of haematological and solid cancers in Australia. Its lead drug candidate is PTX-100, a first in class targeted therapy which can disrupt the RAS family pathway by inhibiting the prenylation action of the enzyme GGT-1. The company was formerly known as Virax Holdings Limited and changed its name to Prescient Therapeutics Limited in December 2014. Prescient Therapeutics Limited was incorporated in 1986 and is based in Melbourne, Australia.
Fundamental trends
Financial statements
Loading…
Key metrics
Market cap
$89.38M
P/E (trailing)
—
P/E (forward)
8.50
EPS (trailing)
-0.01
Dividend yield
—
Payout ratio
0.0%
Beta
0.77
EV / EBITDA
—
Price / Book
5.31
ROE
-54.3%
Operating margin
-344.0%
Net margin
-207.7%
Total cash
$9.77M
Total debt
$272,915
Current ratio
12.95
Debt / Equity
0.02
Free cash flow
$-4.78M
Avg volume
985,406
Latest annual results
(FY ending 30 Jun 2025)
- Revenue—
- Gross profit—
- Operating income-$11.90M
- Net income-$7.32M
- Diluted EPS-0.01
- Free cash flow-$7.24M
- Net debt-$6.91M